Overview

Acceptability of a Fixed Combination of Fenofibrate and Metformin

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
Phase:
Phase 3
Details
Lead Sponsor:
Solvay Pharmaceuticals
Treatments:
Fenofibrate
Metformin